Medizinischen Universität Lausitz – Carl Thiem

At the Medizinischen Universität Lausitz – Carl Thiem, investigators are evaluating the addition of ribociclib to standard endocrine therapy for patients with HR‑positive, HER2‑negative early breast cancer to enhance invasive disease‑free survival.

• Adjuvant targeted therapy strategies
• CDK4/6 inhibitor combinations
• Outcomes in early‑stage disease

This research underscores the department’s focus on advancing systemic treatment options for gynecologic oncology patients.

Researchers are comparing the novel antibody elranatamab with established regimens such as EPd, PVd and Kd in individuals with relapsed/refractory multiple myeloma who have previously received anti‑CD38 therapy, aiming to identify more effective therapeutic options.

• Monoclonal antibody approaches
• Combination regimens after anti‑CD38 exposure
• Improving outcomes in hematologic malignancies

These trials contribute to broader European efforts to enhance care for patients with challenging blood cancers.